A Stable Prostacyclin Analogue Reduces High Serum TNF-α Levels in Diabetic Patients

Abstract

Aims: To confirm whether a prostacyclin (prostaglandin I₂) affects the increased TNF-α concentration in sera of diabetic patients, we measured serum TNF-α concentration and treated these patients with oral administration of the stable prostacyclin analogue (Beraprost). Twelve of 20 type II diabetic patients were investigated for follow up-study and 6 of those patients were for therapy with Beraprost for diabetic neuropathy.

Subjects and Methods: Serum TNF-α concentration was quantified by EASIA using monoclonal antibodies directed against distinct epitopes of TNF-α.

Results: In diabetic patients, serum TNF-α concentration was significantly increased compared with that of healthy subjects. The augmented TNF-α concentration in these patients was not decreased by diabetic control using antihyperglycemic agents for 8 weeks but was reduced with oral administration of a stable prostacyclin (prostaglandin I₂) analogue for 5 weeks without any changes of blood glucose levels.

Conclusions: Stable prostacyclin analogue administration for a short term period reduced increased TNF-α levels in diabetic patients, not through the improved hyperglycemic condition but another pathway, probably a cAMP system. These results imply that treatment with the prostacyclin analogue may contribute to the prevention of progression in diabetic complications.

Prostacyclin (prostaglandin I₂) - diabetes mellitus - tumor necrosis factor-α (TNF-α)

References

• 1 Amore A, Cirina P, Mitola S, Peruzzi L, Gianoglio B, Rabbone I, Sacchetti C, Cerutti F, Grillo C, Coppo R. Nonenzymatically glycated albumin (Amadori adducts) enhances nitric oxide synthase activity and gene expression in endothelial cells.  Kidney Int. 1997;  51 27-35
• 2 Askari B, Ferreri N R. Regulation of prostacyclin synthesis by angiotensin II and TNF-alpha in vascular smooth muscle.  Prostaglandins Other Lipid Mediat. 2001;  63 175-187
• 3 Benjafield A V, Glenn C L, Wang X L, Colagiuri S, Morris B J. TNFRSF1 B in genetic predisposition to clinical neuropathy and effect on HDL cholesterol and glycosylated hemoglobin in type 2 diabetes.  Diabetes Care. 2001;  24 753-757
• 4 Bullo M, Garcia-Lorda P, Salas-Salvado J. Plasma soluble tumor necrosis factor alpha receptors and leptin levels in normal-weight and obese women: effect of adiposity and diabetes.  Eur J Endocrinol. 2002;  146 325-331
• 5 Coughlan M T, Oliva K, Georgiou H M, Permezel J M, Rice G E. Glucose-induced release of tumour necrosis factor-alpha from human placental and adipose tissues in gestational diabetes mellitus.  Diabetic Med. 2001;  18 921-927
• 6 Crutchley D J, Conanan L B, Que B G. Effects of prostacyclin analogs on the synthesis of tissue factor, tumor necrosis factor-alpha and interleukin-1 beta in human monocytic THP-1 cells.  J Pharmacol Exp Therp. 1994;  271 446-451
• 7 Garvey W T, Maianu L, Zhu J H, Hancock J A, Golichowski A M. Multiple defects in the adipocyte glucose transport system cause cellular insulin resistance in gestational diabetes. Heterogeneity in the number and a novel abnormality in subcellular localization of GLUT4 glucose transporters.  Diabetes. 1993;  42 1773-1785
• 8 Hart P H, Whitty G A, Piccoli D S, Hamilton J A. Control by IFN-gamma and PGE2 of TNF alpha and IL-1 production by human monocytes.  Immunology. 1989;  66 376-383
• 9 Haynes D R, Whitehouse M W, Vernon-Roberts B. The prostaglandin E1 analogue, misoprostol, regulates inflammatory cytokines and immune functions in vitro like the natural prostaglandins E1, E2 and E3.  Immunology. 1992;  76 251-257
• 10 Hotamisligil G S, Arner P, Caro J F, Atkinson R L, Spiegelman B M. Increased adipose tissue expression of tumor necrosis factor-alpha in human obesity and insulin resistance.  J Clin Invest. 1995;  95 2409-2415
• 11 Hotamisligil G S, Peraldi P, Budavari A, Ellis R, White M F, Spiegelman B M. IRS-1-mediated inhibition of insulin receptor tyrosine kinase activity in TNF-alpha- and obesity-induced insulin resistance.  Science. 1996;  271 665-668
• 12 Hotamisligil G S, Shargill N S, Spiegelman B M. Adipose expression of tumor necrosis factor-alpha: direct role in obesity-linked insulin resistance.  Science. 1993;  259 87-91
• 13 Hotamisligil G S, Spiegelman B M. Tumor necrosis factor alpha: a key component of the obesity-diabetes link.  Diabetes. 1994;  43 1271-1278
• 14 Kainoh M, Maruyama I, Nishio S, Nakadate T. Enhancement by beraprost sodium, a stable analogue of prostacyclin, in thrombomodulin expression on membrane surface of cultured vascular endothelial cells via increase in cyclic AMP level.  Biochem Pharmacol. 1991;  41 1135-1140
• 15 Katsuki A, Sumida Y, Murashima S, Murata K, Takarada Y, Ito K, Fujii M, Tsuchihashi K, Goto H, Nakatani K, Yano Y. Serum levels of tumor necrosis factor are increased in obese patients with noninsulin-dependent diabetes mellitus.  J Clin Endocrinol Metab. 1998;  83 859-862
• 16 Kern P A, Saghizadeh M, Ong J M, Bosch R J, Deem R, Simsolo R B. The expression of tumor necrosis factor in human adipose tissue. Regulation by obesity, weight loss, and relationship to lipoprotein lipase.  J Clin Invest. 1995;  95 2111-2119
• 17 Kunkel S L, Spengler M, May M A, Spengler R, Larrick J, Remick D. Prostaglandin E2 regulates macrophage-derived tumor necrosis factor gene expression.  J Biol Chem. 1988;  263 5380-5384
• 18 Langeler E G, Fiers W, van Hinsbergh V W. Effects of tumor necrosis factor on prostacyclin production and the barrier function of human endothelial cell monolayers.  Arteriosclerosis & Thrombosis. 1991;  11 872-881
• 19 Matsuzawa Y, Funahashi T, Nakamura T. Molecular mechanism of metabolic syndrome X: contribution of adipocytokines adipocyte-derived bioactive substances.  Annl NY Acad Sciences. 1999;  892 146-154
• 20 McCarty M F. Interleukin-6 as a central mediator of cardiovascular risk associated with chronic inflammation, smoking, diabetes, and visceral obesity: down-regulation with essential fatty acids, ethanol and pentoxifylline.  Med Hypotheses. 1999;  52 465-477
• 21 Mishima Y, Kuyama A, Tada A, Takahashi K, Ishioka T, Kibata M. Relationship between serum tumor necrosis factor- and insulin resistance in obese men with Type 2 diabetes mellitus.  Diabetes Res Clin Prac. 2001;  52 119-123
• 22 Nishimura S, Satoh J, Toyota T. Serum TNF α levels and diabetic complications in NIDDM patients.  Diabetologia. 1997;  40 (Suppl 1) A601
• 23 Norman J G, Fink G W, Franz M G. Acute pancreatitis induces intrapancreatic tumor necrosis factor gene expression.  Arch Surgery. 1995;  130 966-970
• 24 Ollivier V, Parry G C, Cobb R R, deProst D, Mackman N. Elevated cyclic AMP inhibits NF-kappaB-mediated transcription in human monocyclic cells and endothelial cells.  J Biol Chem. 1996;  271 20828-20835
• 25 Qiang X, Satoh J, Sagara M, Fukuzawa M, Masuda T, Miyaguchi S, Takahashi K, Toyota T. Gliclazide inhibits diabetic neuropathy irrespective of blood glucose levels in streptozotocin-induced diabetic rats.  Metabolism. 1998 a;  47 977-981
• 26 Qiang X, Satoh J, Sagara M, Fukuzawa M, Masuda T, Sakata Y, Muto G, Muto Y, Takahashi K, Toyota T. Inhibitory effect of troglitazone on diabetic neuropathy in streptozotocin-induced diabetic rats.  Diabetologia. 1998 b;  41 1321-1326
• 27 Sagara M, Satoh J, Wada R, Yagihashi S, Takahashi K, Fukuzawa M, Muto G, Muto Y, Toyota T. Inhibition of development of peripheral neuropathy in streptozotocin-induced diabetic rats with N-acetylcysteine.  Diabetologia. 1996;  39 263-269
• 28 Sagara M, Satoh J, Zhu X P, Takahashi K, Fukuzawa M, Muto G, Muto Y, Toyota T. Inhibition with N-acetylcysteine of enhanced production of tumor necrosis factor in streptozotocin-induced diabetic rats.  Clin Immunol Immunopathol. 1994;  71 333-337
• 29 Satoh J, Seino H, Abo T, Tanaka S, Shintani S, Ohta S, Tamura K, Sawai T, Nobunaga T, Oteki T. Recombinant human tumor necrosis factor alpha suppresses autoimmune diabetes in nonobese diabetic mice.  J Clin Invest. 1989;  84 1345-1348
• 30 Shteinberg D, Halak M, Shapiro S, Kinarty A, Sobol E, Lahat N, Karmeli R. Adbominal aortic aneurys and aortic occlusive disease: a comparison of risk factors and inflammatory response.  Euro J Vasc Endocasc Surg. 2000;  20 462-465
• 31 Stephens J M, Pekala P H. Transcriptional repression of the GLUT4 and C/EBP genes in 3T3-L1 adipocytes by tumor necrosis factor-alpha.  J Biol Chem. 1991;  266 21839-21845
• 32 Sushil K J, Krishnaswamy K, Gideon L, Robert M, Joseph Jr A B. Hyperketonemia increases tumor necrosis factor-α secretion in cultured U937 monocytes and type 1 diabetic patients and is apparently mediated by oxidative stress and cAMP deficiency.  Diabetes. 2002;  51 2287-2293
• 33 Tanaka S, Seino H, Satoh J, Fujii N, Rikiishi H, Zhu X P, Takahashi K, Sagara M, Nobunaga T, Toyota T. Increased in vivo production of tumor necrosis factor after development of diabetes in nontreated, long-term diabetic BB rats.  Clin Immunol Immunopathol. 1992;  62 258-263
• 34 Yang X D, Tisch R, Singer S M, Cao Z A, Liblau R S, Schreiber R D, McDevitt H O. Effect of tumor necrosis factor alpha on insulin-dependent diabetes mellitus in NOD mice. I. The early development of autoimmunity and the diabetogenic process.  J Exp Med. 1994;  180 995-1004
• 35 Yokoyama H, Deckert T. Central role of TGF-β in the pathogenesis of diabetic nephropathy and macrovascular complications: a hypothesis.  Diabetic Med. 1996;  13 313-320
• 36 Yuuki T, Kanda T, Kimura Y, Kotajima N, Tamura J, Kobayashi I, Kshi S. Inflammatory cytokines in vitreous fluid and serum of patients with diabetic vitreoretinopathy.  J Diabetes Comp. 2001;  15 257-259